edap | Focal·One®

The **Global Leader** in Therapeutic Ultrasound



FORWARD-LOOKING Statements & Disclaimer

This presentation has been prepared solely for use at this meeting. The material may be given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to "EDAP," "EDAP TMS," "the company," "we," "us" and "our," refer to EDAP TMS S.A.

Any information in this presentation is subject to modification at any time and the company undertakes no obligation to update you, except to the extent required by applicable law. If an offer of securities is made by the company in the future, prospective investors should rely solely on the prospectus, including the information incorporated by reference into the prospectus. No reliance may be placed for any purposes whatsoever on the information contained in this presentation, or on its completeness, accuracy or fairness. It is the responsibility of each prospective investor to review the prospectus, including the information incorporated by reference into the prospectus and the responsibility of each prospective investor to review the prospectus, including the information incorporated by reference into the prospectus, and to make an independent assessment of the risks and merits of any such offering.

This presentation contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, the clinical status and market acceptance of our HIFU devices, the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the company's filings with the securities and exchange commission and in particular, in the sections "cautionary statement on forward-looking information" and "risk factors" in the company's annual report on form 20-F.

The opinions and clinical experiences presented herein are specific to the featured physicians and/or the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the company, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The presentation is being furnished to you solely for your information, and may not be copied, reproduced, distributed or passed, directly or indirectly, in whole or in part, to any other person.






Company Overview





The **Global Leader** in Innovation and Delivery of Advanced Ultrasound Technologies for both the **Diagnosis and Treatment of Disease**

Core Technologies of Focal One®



Global Market Presence

7 Global Subsidiaries and **350+ Clinical Sites** Offering Our Advanced Ultrasound Technologies

EDAP Offices – United States, France, Germany, Switzerland, South Korea, Japan and Malaysia

EDAP Customer Sites – Over 350 Clinical Sites

GROWING MOMENTUM At Leading Hospitals

61 Focal One Systems in the U.S. at the end of Q3 2024 (32 Academic – 29 Community)



edap Focal One

FOCAL ONE IS THE LEADING FOCAL THERAPY TECHNOLOGY Strong Adoption by the Highest Ranked Prostate Cancer Hospitals in the US



edap **Focal·One**



Prostate Cancer Addressable Market



Prostate Cancer Market Opportunity

1.5 Million New Prostate Cancer Cases Per Year

Region	Nu
Europe	
Asia	
North America	
Latin America	
Africa	
Oceania	
Total	

umber of New Prostate Cancer Cases 473,011 386,424 255,782 225,985 103,050 23,602 **1,467,854**



U.S. PROSTATE CANCER MARKET

3.3 Million

American Men Living with Prostate Cancer (1)

299,010

New Cases Diagnosed Every Year in the US $^{\left(1\right) }$

1 Million


Prostate Biopsies Performed Annually in the US and Increasing Every Year⁽²⁾

35,250

Deaths every year in the US⁽¹⁾

⁽¹⁾ 2024 estimates from the American Cancer Society (<u>www.cancer.org</u>) ⁽²⁾ Bjurlin et al. Standards for prostate biopsy. Curr Opin Urol. 2014

Prostate Cancer is the Most Common Cancer Amongst Men In the US (2024)



11



Total Addressable Market



edap **Focal One**

Global Prostate Cancer Addressable Market

465,000 Global Prostate Cancer Procedures Per Year

165,000 Europe 130,000 Asia 95,000 North America 75,000

edap Focal·One

South America

Based on 2023 Internal Company Estimates




Prostate Cancer Treatment Trends




HISTORICAL TREATMENTS Non-Organ Preserving Cancer Treatments

THE TREND TOWARDS Organ Preserving Cancer Treatments



Jne

FOCAL ONE ROBOTIC FOCAL HIFU FOCAL Therapy Fills an Important Treatment Gap in the Management of Prostate Cancer




Advanced imaging, targeted biopsies, and genomic testing allow for better risk stratification of the prostate cancer patient.

HIFU provides a safe, effective, and minimally invasive option for patients with low, intermediate-risk disease, as well as salvage treatment for failed radiotherapy **Patients** are actively seeking an option **between active surveillance** and **radical therapy**




BRIVING A PARADIGM SHIFT IN PROSTATE CANCER Focal Therapy | The New Emerging Market



 As of 2013. Chen et al. National trends in the management of localized prostate cancer. A population-based analysis 2004-2013. Prostate.
 Internal market estimate



DRIVING A PARADIGM SHIFT IN PROSTATE CANCER HIFU | The Fastest Growing Treatment Option








Focal One[®] Best-in-Class Technology



The leading focal therapy technology **Targeting and Imaging**



edap **Focal·On**e

20

The **Most Advanced Robotic HIFU** Platform In the Hands of Urologists

Robotic Positioning System

Fusion

Focal·One

HIFUsion[®] MRI /

3D Biopsy Fusion

The Leading Platform for Focal Ablation of Prostate

Dynamic Focusing Probe

Integrated Workstation

Compatible With Standard OR Beds

edap Focal One





Favorable Reimbursement



STRONG REIMBURSEMENT Creates Favorable Environment for Growth

CMS Hospital Outpatient Prospective Payment System - 2023 Final rule
 CMS Hospital Outpatient Prospective Payment System - 2022 Final rule
 CMS Hospital Outpatient Prospective Payment System - 2025 Final rule



- 1. APC Level 6 Under CMS for CY23 and CY24 ^(1,3)
- 2. 90% Increase in Reimbursement in 2023 ^(1,2)
- 3. APC Level 6 Maintained by CMS in 2025⁽³⁾



Hospital Outpatient Medicare Payment

Procedure	CPT [®] Code	2024	2025	% Change
Prostate Brachytherapy	55875	\$4,930 ⁽¹⁾	\$5,084 ⁽²⁾	3.1%
Cryo	55873	\$8,777 ⁽¹⁾	\$9,247 ⁽²⁾	5.4%
MRI Transurethral Ultrasound Ablation	C9734 / 55882	\$12,553 ⁽¹⁾	\$12,992 ⁽²⁾	3.5%
HIFU	55880	\$8,777 ⁽¹⁾	\$9,247 ⁽²⁾	5.4%
Laparoscopic Prostatectomy	55866	\$9,808 ⁽¹⁾	\$10,411	6.1%

(Laparoscopic Prostatectomy with or without Robotic Assistance and/or nerve-sparing)

(1) Medicare Payment (National Average. From on CMS Hospital Outpatient Prospective Payment System – 2024 Final rule (2) Medicare Payment (National Average. From on CMS Hospital Outpatient Prospective Payment System – 2025 Final rule

Favorable Physician Payment

Procedure	CPT [®] Code	Work RVU (2024) ⁽¹⁾	Physician Payment (Medicare - 2024)	Work RVU (2025) ⁽²⁾	Physician Payment (Medicare - 2025)
Prostate Brachytherapy	55875	13.46	\$776	13.46	\$763
Cryo	55873	13.60	\$760	13.60	\$744
MRI Transurethral Ultrasound Ablation	55882	-	-	11.50	\$579
HIFU	55880	17.73	\$972	17.73	\$951
Laparoscopic Prostatectomy	55866	22.46	\$1,183	22.46	\$1,157

(Laparoscopic Prostatectomy with or without Robotic Assistance and/or nerve-sparing)

(1) CMS Physician Fee Schedule – CY 2024 Final rule (2) CMS Physician Fee Schedule – CY 2025 Final rule





Strong Supporting Clinical Evidence



CLINICAL EVIDENCE SUPPORTS HIFU Proven Clinical Evidence Supporting HIFU

Published Results Confirm Reproducible Outcomes for Prostate Cancer with HIFU

1000+ Peer-Reviewed Publications Supporting HIFU in the Treatment of Prostate Cancer ⁽¹⁾

The Trifecta Outcome for Prostate Cancer Management

1. Cancer2. MaintainingControlUrinary Control


3. Preservation of Sexual Function



CLINICAL EVIDENCE SUPPORTS HIFU

HIFI - Prospective Multicentric Comparative Study Focal One HIFU vs Radical Prostatectomy

Published in European Urology – December 2024



Prospective, Comparative, Multicentric, non-inferiority clinical trial comparing HIFU to Radical Prostatectomy (RP)

3,328 patients treated (1,967 HIFU - 1,361 RP) across 46 centers

90% of HIFU patients treated with Focal One

Comparable Cancer Control (**90%** STFS for HIFU vs **86%** for RP; p = 0.008)


Superior functional outcomes for HIFU

- Urinary Continence significantly better after HIFU
- Significantly lower stress incontinence after HIFU
- Erectile Function less impaired (IIEF-5: $\Delta = -7 vs 13$)

Rischmann et al. HIFI Trial: HIFU vs Radical Prostatectomy for Localized Prostate Cancer in 3328 Cases. Final Results. [P2-06]. J. Urol. 2024; Vol. 211, No. 5S2, Supplement, Friday, May 3, 2024.

29

FARP - Randomized Control Trial Comparing Focal Ablation vs Robotic Prostatectomy



Prospective, Comparative, Randomized, non-inferiority clinical trial comparing Focal Ablation to Robot-Assisted Radical Prostatectomy

213 patients included

Equivalent Oncologic Control at 2 years (94% TFF vs 92%)

Superior Functional Outcomes after HIFU

25% of patients refused surgical treatment after being randomized to RP and opted for FA

Robotic Surgery

Baco et al. A Randomized Clinical Trial Comparing Focal Ablation and Radical Prostatectomy in Patients with Unilateral Clinically Significant Prostate Cancer. Intention to Treat Analysis at Two-Year Follow-Up. [PD39-06]. J. Urol. 2024; Vol. 211, No. 5S, Supplement, Sunday, May 5, 2024.


Baco et al. Focal Ablation Versus Radical Prostatectomy for Intermediate-Risk Prostate Cancer: Interim Analysis of a Randomized Controlled Trial. The Journal of Urology. Vol. 206, No. 3S, Supplement, Sunday, September 12, 2021





BPH & Endometriosis Large Market Opportunities For Expansion

The Breadth of Therapeutic Ultrasound Targeting Large Incidence Cancer and Benign Conditions



⁽¹⁾ Newly Diagnosed Cases per year From World Health Organization – Globocan 2020

⁽²⁾ From WHO and Habib N et al. Bowel Endometriosis: Current Perspectives on Diagnosis and Treatment. Int J Womens Health. 2020

⁽³⁾ Xu et al. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. Am J Mens Health. 2021

(4) Based on UN Population Division and Goehring et al. Epidemiology of benign breast disease, with special attention to histologic types, Epidemiol Rev. 1997

⁽⁵⁾ Based on UN Population Division and Bomeli et al. Evaluation of a thyroid nodule. Otolaryngol Clin North Am. 2010

edap Focal One

32

BENIGN PROSTATIC HYPERPLASIA (BPH) MARKET

94 Million

Global cases of BPH in 2019⁽¹⁾

15 Million

US men are affected by BPH/LUTS ⁽²⁾

600,000

US men aged 65+ newly diagnosed annually ⁽³⁾

Leveraging Expertise in **Robotic HIFU** and Prostate for **BPH**

12.2 Million men actively managed for BPH/LUTS:

- 55% under Drug Management ⁽⁴⁾
- 35% under Watchful Waiting ⁽⁴⁾
- 300,000+ Active Surgical Treatments ⁽⁵⁾

Focal One Robotic HIFU technology has the potential to provide a **non-invasive** option that can safely treat BPH-related symptoms while avoiding the side effects of standard surgical treatments.

10,000s PCa treatments constitute a robust foundation to build upon for a BPH strategy

- (2) Egan K B. Urologic Clinics of North America. 2016
- (3) Urologic Diseases in America. 2024. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2024
- (4) Vuichoud et al. Can J Urol. 2015
- (5) Internal market estimate

⁽¹⁾ Fentahun et al. The Lancet Healthy Longevity. 2022

BPH: FOCAL ONE CLINICAL STUDY PROGRESS Building High-Level Evidence in the Treatment of Benign Prostate Hyperplasia

Feasibility Study Completed Phase I-II Study Recruiting **US FDA Study** Scoping





- Monocentric Feasibility Study (9 patients)
- Confirmed Safety and potential for improvement of BPH-related symptoms

- First Patients Treated
- Phase I: Three-center study HIFU dose escalation
- Phase II: Multi-center Study Safety and Efficacy of Final HIFU Parameters as defined in Phase 1
- Multi-center Study to be defined based on Phase I-II Study findings

U.S. ENDOMETRIOSIS MARKET

Leveraging Expertise in **Robotic HIFU** For **Endometriosis**

6.5 Million

US Women Have Endometriosis (1)

1.3 Million^(20%)

Cases are Deep Infiltrating Endometriosis (DIE) in the US ⁽²⁾

11% of US Women

are Affected by Endometriosis⁽²⁾

edap | Focal One


Common symptoms of Rectal Endometriosis may include various conditions (acute pelvic pain, constipation, diarrhea, rectal bleeding), all of which negatively impact quality of life and ability to become pregnant.

Current treatment options are lacking and limited to hormonal and/or surgical management

Focal One has the potential of offering a noninvasive option with the ability of **Reducing Symptoms** and **Improving Quality of Life**

⁽¹⁾ Office of Women's Health (www.womenshealth.gov)
⁽²⁾ D'Alterio MN et al. Management Challenges of Deep Infiltrating Endometriosis. Int J Fertil Steril. 2021 Apr;15(2):88-94. doi: 10.22074/IJFS.2020.134689. Epub 2021 Mar 11. PMID: 33687160; PMCID: PMC8052801

ENDOMETRIOSIS: FOCAL ONE CLINICAL STUDY PROGRESS Building High-Level Evidence in the Treatment of Deep Infiltrating Rectal Endometriosis



- Feasibility (20 patients)
- Published in the Journal of Ultrasound in Obstetrics and Gynecology in 2020
- Multicenter Safety and Efficacy Study (60 patients)
- Completed in March 2022
- Manuscript Accepted for Publication

- Multicenter Double-Blind Randomized Controlled Trial (RCT)
- Enrollment completed (60 patients) in less than 9 months

- Follow-up of all patients in progress
- 85% of Sham Group patients elected and received HIFU Treatment



Key Financial Data




Financial Highlights as of September 30, 2024

THREE MONTHS ENDED SEPTEMBER 30TH

(in \$Million USD except per share data)	2023	2024
Revenue	12.7	14.4
Gross Profit	4.5	5.7
Gross Margin	35.5%	39.4%
Operating Profit (Loss)	(6.0)	(6.4)
Net Income (Loss)	(4.3)	(7.0)
Earnings (Loss) Per Share	(0.12)	(0.19)

Year to Date 2024

\$47.6 Million Total Revenue (+7.7% YoY) +14.9% HIFU Growth



NOTE: Translated for convenience of the reader to U.S. dollars at the 2024 average three months' exchange rate of 1 Euro = 1.1010 USD, and 2023 average three months' exchange rate of 1 Euro = 1.0814 USD

Balance Sheet Highlights as of September 30, 2024

(in \$Million USD)	September 30, 2024	September 30, 2023
Cash and Cash Equivalents	28.4	50.5
Other Current Assets	42.9	34.5
Fixed and Other Non-Current Assets	16.8	13.8
	88.1	98.7
Current Liabilities	32.7	27.5
Non-Current Liabilities	7.8	7.7
Shareholders' Equity	47.5	63.6
	88.1	98.7

Balance Sheet As Of:

Note: Translated for convenience of the reader to U.S. dollars at the exchange rate of 1 Euro = 1.1145 USD, on September 30, 2024 and and at the noon buying rate of 1 euro = 1.0584 USD on September 30, 2023.

SUMMARY Positioned for Growth

• Large Addressable Markets in Men's and Women's Health

Johnson & Johnson

INTUÎTIVE

- Growing Install base of Leading Tier 1 Academic and Community Hospitals
- Differentiated Non-Invasive Robotic HIFU Technology Solving Unmet Needs for Prostate Cancer, BPH and Endometriosis

ACCURAY

Mazor Robotics

Medtronic

edap Focal One

- Strong Clinical Evidence with Favorable Reimbursement in Place
- Proven Management Team from Industry-Leading MedTech Companies

edap | Focal·One®

The Global Leader in Therapeutic Ultrasound

